DEXCOM INC
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 8, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| DEXCOM, INC.(Registrant) | ||
| Dated: February 8, 2024 | By: | /s/ JEREME M. SYLVAIN |
|---|---|---|
| Jereme M. Sylvain,Executive Vice President and Chief Financial Officer(Principal Financial and Accounting Officer) | ||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Kevin R. Sayer and Jereme M. Sylvain, jointly and severally, his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto each of said attorneys-in-fact and agents, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ KEVIN R. SAYER | Chairman of the Board of Directors, President and Chief Executive Officer (Principal Executive Officer) | February 8, 2024 |
| Kevin R. Sayer | ||
| /s/ JEREME M. SYLVAIN | Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) | February 8, 2024 |
| Jereme M. Sylvain | ||
| /s/ MARK G. FOLETTA | Lead Independent Director | February 8, 2024 |
| Mark G. Foletta | ||
| /s/ STEVEN R. ALTMAN | Director | February 8, 2024 |
| Steven R. Altman | ||
| /s/ NICHOLAS AUGUSTINOS | Director | February 8, 2024 |
| Nicholas Augustinos | ||
| /s/ RICHARD A. COLLINS | Director | February 8, 2024 |
| Richard A. Collins | ||
| /s/ KAREN DAHUT | Director | February 8, 2024 |
| Karen Dahut | ||
| /s/ RIMMA DRISCOLL | Director | February 8, 2024 |
| Rimma Driscoll | ||
| /s/ BRIDGETTE P. HELLER | Director | February 8, 2024 |
| Bridgette P. Heller | ||
| /s/ BARBARA E. KAHN | Director | February 8, 2024 |
| Barbara E. Kahn | ||
| /s/ KYLE MALADY | Director | February 8, 2024 |
| Kyle Malady | ||
| /s/ ERIC J. TOPOL | Director | February 8, 2024 |
| Eric J. Topol, M.D. | ||
DexCom, Inc.
Index to Consolidated Financial Statements
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets | F-4 |
| Consolidated Statements of Operations | F-5 |
| Consolidated Statements of Comprehensive Income | F-6 |
| Consolidated Statements of Stockholders’ Equity | F-7 |
| Consolidated Statements of Cash Flows | F-8 |
| Notes to Consolidated Financial Statements | F-10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.